These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 12111107)

  • 41. Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition.
    Seaton C; Ignas J; Muchohi S; Kokwaro G; Maitland K; Thomson AH
    J Antimicrob Chemother; 2007 Apr; 59(4):681-9. PubMed ID: 17347177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
    Min Y; Qiang F; Peng L; Zhu Z
    Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Population pharmacokinetic modeling and evaluation of propofol from multiple centers].
    Ye HB; Zheng H; Zhang XA; Chi XJ; Chen WY; Xu JG; Li JH; Rui JZ
    Yao Xue Xue Bao; 2010 Dec; 45(12):1550-8. PubMed ID: 21351496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
    Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
    Bergmann TK; Brasch-Andersen C; Gréen H; Mirza M; Pedersen RS; Nielsen F; Skougaard K; Wihl J; Keldsen N; Damkier P; Friberg LE; Peterson C; Vach W; Karlsson MO; Brosen K
    Pharmacogenomics J; 2011 Apr; 11(2):113-20. PubMed ID: 20368717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
    Ellis AG; Webster LK
    Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
    Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
    Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients.
    Yukawa E; Mori S; Ueda K; Nakada Y
    J Clin Pharm Ther; 2007 Dec; 32(6):573-8. PubMed ID: 18021334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
    Brouwer E; Verweij J; Hauns B; Loos WJ; Nooter K; Mross K; Stoter G; Sparreboom A
    Anal Biochem; 1998 Aug; 261(2):198-202. PubMed ID: 9716422
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
    Briasoulis E; Karavasilis V; Tzamakou E; Haidou C; Piperidou C; Pavlidis N
    Anticancer Drugs; 2002 Jun; 13(5):481-9. PubMed ID: 12045459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
    Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
    Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.